SCHEDULE: Highbridge Capital Exits Matinas BioPharma Stake

Highbridge Capital Management, LLC has reported a complete divestment of its beneficial ownership in Matinas BioPharma Holdings, Inc., reducing its stake to 0%.

Summary

• Highbridge Capital Management, LLC, an investment adviser, has filed an Amendment No. 2 to Schedule 13G regarding its holdings in Matinas BioPharma Holdings, Inc.
• The filing indicates that Highbridge Capital Management, LLC no longer beneficially owns any shares of Matinas BioPharma Holdings, Inc. common stock.
• Their aggregate beneficial ownership has decreased to 0.00 shares, representing 0% of the class.
• The event requiring this filing occurred on September 30, 2025.

Sentiment

Score: 3

Explanation: The complete divestment by an institutional investor is generally a negative signal for the issuer, suggesting a lack of confidence or a strategic shift away from the company by that investor.

Positives

• For Highbridge Capital Management, LLC, the filing confirms the successful divestment of their position in Matinas BioPharma Holdings, Inc.

Negatives

• Highbridge Capital Management, LLC has fully divested its beneficial ownership in Matinas BioPharma Holdings, Inc., reducing its stake to 0%.
• The complete exit of an institutional investor like Highbridge Capital Management, LLC could be perceived negatively by the market for Matinas BioPharma Holdings, Inc.

Risks

• The filing itself does not detail specific risks for Matinas BioPharma Holdings, Inc. However, the complete divestment by an institutional investor could signal a perceived increase in risk or lack of confidence in the issuer's future prospects by that investor.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Matinas BioPharma Holdings, Inc.'s future performance or strategic direction.

Management Comments

• Highbridge Capital Management, LLC certifies that, to the best of its knowledge and belief, the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

This filing reflects a change in institutional ownership for Matinas BioPharma Holdings, Inc. and does not provide broader industry trends or competitive analysis. The divestment by Highbridge Capital Management, LLC could be a specific investment decision related to their portfolio strategy or a re-evaluation of Matinas BioPharma's prospects.

Stakeholder Impact

• Shareholders: Existing shareholders of Matinas BioPharma Holdings, Inc. may perceive the divestment by Highbridge Capital Management, LLC as a negative signal, potentially leading to downward pressure on the stock price.

Key Dates

Keywords

Schedule 13G, Amendment No. 2, Matinas BioPharma Holdings Inc., Highbridge Capital Management LLC, beneficial ownership, common stock, divestment, institutional investor, SEC filing